Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CEL | P19835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11154618 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7613945 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL11022414 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL5883485 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7614811 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7619522 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7614743 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7615078 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7618517 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL29263636 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | claimed |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4353713-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Kinki University (JP) | 2024-04-17 | — | — | EP | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-116478154-A | Quinuclidine derivative and preparation method and application thereof | 北京大学宁波海洋药物研究院 | 2023-07-25 | — | — | CN | disclosed |
| CN-116212960-A | Aryloxy cyclic ether skeleton metal complex catalyst and preparation method and application thereof | 万华化学集团股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2022260016-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 学校法人近畿大学 | 2022-12-15 | — | — | WO | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| WO-2002076995-A2 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0479601-B1 | Piperidine derivatives and their use as antiarrhythmic agents | AJINOMOTO KK (JP) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5229400-A | Cardiovascular disorders | AJINOMOTO CO., INC. (JP) | 1993-07-20 | — | — | US | disclosed |
| EP-0479601-A2 | Piperidine derivatives and their use as antiarrhythmic agents | Ajinomoto Co., Inc. (JP) | 1992-04-08 | — | — | EP | disclosed |
| EP-0159784-B1 | CARBACYCLIN ANALOGUES | THE UPJOHN COMPANY (US) | 1989-06-07 | — | — | EP | disclosed |
| US-4683330-A | ANTICOAGULANTS, ANTIULCER AGENTS | THE UPJOHN COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| EP-0159784-A1 | Carbacyclin analogues | THE UPJOHN COMPANY (US) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | SIGMAR1 3530/4885CYP1A2 4026/4885EPHX1 342/4885 |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1G, CACNA1I, CACNA1H | SIGMAR1 2729/4885CYP1A2 3930/4885EPHX1 4243/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | SIGMAR1 2984/4885CYP1A2 4252/4885EPHX1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.